Discontinued — last reported Q4 '25
Operating
D&A
Gilead Sciences D&A increased by 563.3% to $597.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 0.2%, from $598.00M to $597.00M. Over 4 years (FY 2021 to FY 2025), D&A shows a downward trend with a -5.4% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ4 2025Feb 24, 2026
How to read this metric
Higher levels indicate significant capital investment in infrastructure or acquisitions, while lower levels may suggest aging assets or limited capital expenditure.
Detailed definition
This represents the non-cash expense allocated to the cost of tangible and intangible assets over their useful lives. Be...
Peer comparison
High in capital-intensive industries like manufacturing and healthcare devices; lower in service-based sectors.
Metric ID:
depreciation_and_amortization_cfHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $440.00M | $441.00M | $445.00M | $445.00M | $445.00M | $445.00M | $445.00M | $546.00M | $598.00M | $598.00M | $597.00M | $596.00M | $98.00M | $94.00M | $598.00M | $599.00M | $93.00M | $90.00M | $597.00M |
| QoQ Change | — | +0.2% | +0.9% | +0.0% | +0.0% | +0.0% | +0.0% | +22.7% | +9.5% | +0.0% | -0.2% | -0.2% | -83.6% | -4.1% | +536.2% | +0.2% | -84.5% | -3.2% | +563.3% |
| YoY Change | — | — | — | — | +1.1% | +0.9% | +0.0% | +22.7% | +34.4% | +34.4% | +34.2% | +9.2% | -83.6% | -84.3% | +0.2% | +0.5% | -5.1% | -4.3% | -0.2% |
Range$90.00M – $599.00M
CAGR+7.0%
Avg YoY Growth-2.7%
Median YoY Growth+0.5%
D&A at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's d&a?
- Gilead Sciences (GILD) reported d&a of $597.00M in Q4 2025.
- How has Gilead Sciences's d&a changed year-over-year?
- Gilead Sciences's d&a decreased by 0.2% year-over-year, from $598.00M to $597.00M.
- What is the long-term trend for Gilead Sciences's d&a?
- Over 4 years (2021 to 2025), Gilead Sciences's d&a has grown at a -5.4% compound annual growth rate (CAGR), from $1.72B to $1.38B.
- What does d&a mean?
- The non-cash accounting expense for the wear and tear or expiration of assets.